A multidisciplinary approach to study the effects of balneotherapy and mud-bath therapy treatments on fibromyalgia

Clinical and Experimental Rheumatology

Volumn 31, Issue SUPPL.79, 2013, Pages 111-120

  Bazzichi, Laura ^a   Da Valle, Ylenia ^a   Rossi, Alessandra ^a   Giacomelli, Camillo ^a   Sernissi, Francesca ^a   Giannaccini, Gino ^a   Betti, Laura ^a   Ciregia, Federica ^a   Giusti, Laura ^a   Scarpellini, Pietro ^a   Dell'Osso, Liliana ^a   Marazziti, Donatella ^a   Bombardieri, Stefano ^a   Lucacchini, Antonio ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Balneotherapy; Biomarkers; Fibromyalgia syndrome; Mud bath therapy; Proteomics

Indexed keywords

ADENOSINE TRIPHOSPHATE; BRAIN DERIVED NEUROTROPHIC FACTOR; GLYCOPROTEIN; OXYTOCIN; PHOSPHOGLYCERATE MUTASE; PHOSPHOGLYCERATE MUTASE 1; SEROTONIN TRANSPORTER; TRANSALDOLASE; TRANSALDOLASE 1; UNCLASSIFIED DRUG; ZINC ALPHA 2 GLYCOPROTEIN 1;

ADULT; AGED; ARTICLE; BALNEOTHERAPY; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROMYALGIA; FIBROMYALGIA IMPACT QUESTIONNAIRE; HUMAN; MALE; MASS SPECTROMETRY; MUD BATH THERAPY; MUD THERAPY; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; PAIN ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SALIVA ANALYSIS; SHORT FORM 36; TREATMENT DURATION; TWO DIMENSIONAL ELECTROPHORESIS;

EID: 84892474939     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (65)

1. WOLFE F, SMYTHE HA, YUNUS MB et al.: The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the multicenter criteria committee. Arthritis Rheum 1990; 33: 160-72.
2. SARZI-PUTTINI P, ATZENI F, DI FRANCO M et al.: Dysfunctional syndromes and fibromyalgia: a 2012 critical digest. Clin Exp Rheumatol 2012; 30 (Suppl. 74): 143-51.
3. SALAFFI F, SARZI-PUTTINI P: Old and new criteria for the classification and diagnosis of fibromyalgia: comparison and evaluation. Clin Exp Rheumatol 2012; 30 (Suppl. 74): 3-9.
4. CASTELLI L, TESIO V, COLONNA F et al.: Alexithymia and psychological distress in fibromyalgia: prevalence and relation with quality of life. Clin Exp Rheumatol 2012; 30 (Suppl. 74): 70-7.
5. BAZZICHI L, SERNISSI F, CONSENSI A, GIACOMELLI C, SARZI-PUTTINI P: Fibromyalgia: a critical digest of the recent literature. Clin Exp Rheumatol 2011; 29 (Suppl. 69): S1-11.
6. ALOK R, DAS SK, AGARWAL GG, SALWAHAN L, SRIVASTAVA R: Relationship of severity of depression, anxiety and stress with severity of fibromyalgia. Clin Exp Rheumatol 2011; 29 (Suppl. 69): S70-2.
7. ALCIATI A, SARZI-PUTTINI P, BATTICCIOTTO A et al.: Overactive lifestyle in patients with fibromyalgia as a core feature of bipolar spectrum disorder. Clin Exp Rheumatol 2012; 30 (Suppl. 74): 122-8.
8. SALAFFI F, DE ANGELIS R, GRASSI W: Marche Pain Prevalence; Investigation Group (MAPPING) study. Prevalence of musculoskeletal conditions in an Italian population sample: results of a regional communitybased study. I. The MAPPING study. Clin Exp Rheumatol 2005; 23: 819-28.
9. WOLFE F, ROSS K, ANDERSON J, RUSSEL IJ, HEBERT L: The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 1995; 1: 19-28.
10. RIVERA J, REJAS-GUTIé;RREZ J, VALLEJO MA, ESTEVE-VIVES J, DE SALAS-CANSADO M; ICAF Group: Prospective study of the use of healthcare resources and economic costs in patients with fibromyalgia after treatment in routine medical practice. Clin Exp Rheumatol 2012; 30 (Suppl. 74): 31-8.
11. SPAETH M: Epidemiology, costs, and the economic burden of fibromyalgia. Arthritis Res Ther 2009; 11: 117.
12. DADABHOY D, CROFFORD LJ, SPAETH M, RUSSELL IJ, CLAUW DJ: Biology and therapy of fibromyalgia. Evidence-based biomarkers for fibromyalgia syndrome. Arthritis Res Ther 2008; 10: 211.
13. BAZZICHI L, ROSSI A, GIACOMELLI C, BOMBARDIERI S: Exploring the abyss of fibromyalgia biomarkers. Clin Exp Rheumatol 2010; 28 (Suppl. 63): S125-30.
14. DöNMEZ S, PAMUK öN, üMIT EG, TOP MS: Autoimmune rheumatic disease associated symptoms in fibromyalgia patients and their influence on anxiety, depression and somatisation: a comparative study. Clin Exp Rheumatol 2012; 30 (Suppl. 74): 65-9.
15. SOMMER C, HäUSER W, ALTEN R et al.: Drug therapy of fibromyalgia syndrome. Systematic review, meta-analysis and Guideline. Schmerz 2012; 26: 297-310.
16. LAUCHE R, HäUSER W, JUNG E et al.: Patient-related predictors of treatment satisfaction of patients with fibromyalgia syndrome: results of a cross-sectional survey. Clin Exp Rheumatol 2013; 31 (Suppl. 79): S34-40.
17. KoäLLNER V, HäUSER W, KLIMCZYK K et al.: Psychotherapy for patients with fibromyalgia syndrome. Systematic review, meta-analysis and guideline. Schmerz 2012; 26: 291-6.
18. LANGHORST J, HäUSER W, BERNARDY K et al.: Complementary and alternative therapies for fibromyalgia syndrome. Systematic review, meta-analysis and guideline. Schmerz 2012; 26: 311-7.
19. WINKELMANN A, HäUSER W, FRIEDEL E et al.: Physiotherapy and physical therapies for fibromyalgia syndrome. Systematic review, meta-analysis and guideline. Schmerz 2012; 26: 276-86.
20. FALAGAS ME, ZARKADOULIA E, RAFAILIDIS PI: The therapeutic effect of balneotherapy: evaluation of the evidence from randomised controlled trials. Int J Clin Pract 2009; 63: 1068-84.
21. van EIJK-HUSTINGS Y, KROESE M, TAN F, BOONEN A, BESSEMS-BEKS M, LANDEWé R: Challenges in demonstrating the effectiveness of multidisciplinary treatment on quality of life, participation and health care utilisation in patients with fibromyalgia: a randomised controlled trial. Clin Rheumatol 2013; 32: 199-209.
22. LAWSON K: Treatment options and patient perspectives in the management of fibromyalgia: future trends. Neuropsychiatr Dis Treat 2008; 4: 1059-71.
23. IANNUCCELLI C, MANNOCCI F, GUZZO MP et al.: Complementary treatment in fibromyalgia: combination of somatic and abdominal acupuncture. Clin Exp Rheumatol 2012; 30 (Suppl. 74): 112-6.
24. VELTRI A, SCARPELLINI P, PICCINNI A et al.: Methodological approach to depressive symptoms in fibromyalgia patients. Clin Exp Rheumatol 2012; 30 (Suppl. 74): 136-42.
25. BAPTISTA AS, VILLELA AL, JONES A, NATOUR J: Effectiveness of dance in patients with fibromyalgia: a randomized, singleblind, controlled study. Clin Exp Rheumatol 2012; 30 (Suppl. 74): 18-23.
26. CARBONELL-BAEZA A, APARICIO VA, CHILLóN P, FEMIA P, DELGADO-FERNANDEZ M, RUIZ JR: Effectiveness of multidisciplinary therapy on symptomatology and quality of life in women with fibromyalgia. Clin Exp Rheumatol 2011; 29 (Suppl. 69): S97-103.
27. MARTíN J, TORRE F, PADIERNA A et al.: Six-and 12-month follow-up of an interdisciplinary fibromyalgia treatment programme: results of a randomised trial. Clin Exp Rheumatol 2012; 30 (Suppl. 74): 103-11.
28. FIORAVANTI A, BELLISAI B, CAPITANI S, MANICA P, PAOLAZZI G, GALEAZZI M: Phytothermotherapy: a possible complementary therapy for fibromyalgia patients. Clin Exp Rheumatol 2009; 27 (Suppl. 56): S29-32.
29. BENDER T, KARAGuäLLE Z, BáLINT GP, GUTENBRUNNER C, BáLINT PV, SUKENIK S: Hydrotherapy, balneotherapy, and spa treatment in pain management. Rheumatol Int 2005; 25: 220-4.
30. CIMBIZ A, BAYAZIT V, HALLACELI H, CAVLAK U: The effect of combined therapy (spa and physical therapy) on pain in various chronic diseases. Complement Ther Med 2005; 13: 244-50.
31. GUIDELLI GM, TENTI S, DE NOBILI E, FIORAVANTI A: Fibromyalgia syndrome and spa therapy: myth or reality?. Clin Med Insights Arthritis Musculoskelet Disord 2012; 5: 19- 26.
32. BAZZICHI L, CIREGIA F, GIUSTI L et al.: Detection of potential markers of primary fibromyalgia syndrome in human saliva. Proteomics Clin Appl 2009; 3: 1296-304.
33. BURCKHARDT CS, CLARK SR, BENNETT RM: The fibromyalgia impact questionnaire: development and validation. J Rheumatol 1991; 18: 728-33.
34. SARZI-PUTTINI P, ATZENI F, FIORINI T et al.: Validation of an Italian version of the Fibromyalgia Impact Questionnaire (FIQ-I). Clin Exp Rheumatol 2003; 21: 459-64.
35. WEBSTER K, CELLA D, YOST K: The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretation. Health Qual Life Outcomes 2003; 1: 79.
36. FRIES JF, SPITZ P, KRAINES RG, HOLMAN HR: Measurement of patient outcome in arthritis. Arthritis Rheum 1980; 23: 137-45.
37. RANZA R, MARCHESONI A, CALORI G et al.: The Italian version of the Functional Disability Index of the Health Assessment Questionnaire. A reliable instrument for multicenter studies on rheumatoid arthritis. Clin Exp Rheumatol 1993; 11: 123-8.
38. BRAZIER JE, HARPER R, JONES NM: Validating the SF-36 health survey questionnaire: new outcome measure for primary care. BMJ 1992; 305: 160-4.
39. APA. America n Psychia tric Associa tion: Diagnostic and statistical manual for mental disorder. 4. Washington: APA; DSM-IV.
40. FIRST MB, SPITZER RL, GIBBON M, WILLIAMS JBW: Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition (SCID-I/P). New York, New York State Psychiatric Institute, Biometrics Research, 2001.
41. GIUSTI L, BALDINI C, BAZZICHI L et al.: Proteome analysis of whole saliva: a new tool for rheumatic diseases - the example of Sjoägren's syndrome. Proteomics 2007; 7: 1634-43.
42. GIANNACCINI G, BETTI L, PALEGO L et al.: The expression of platelet serotonin transporter (SERT) in human obesity. BMC Neurosci 2013, 14: 128.
43. MARAZZITI D, DELL'OSSO B, BARONI S et al.: A relationship between oxytocin and anxiety of romantic attachment. Clin Pract Epidemiol Ment Health. 2006; 2: 28.
44. BAZZICHI L, GIANNACCINI G, BETTI L et al.: ATP, calcium and magnesium levels in platelets of patients with primary fibromyalgia. Clin Biochem 2008; 41: 1084-90.
45. CIREGIA F, GIUSTI L, DA VALLE Y et al.: A multidisciplinary approach to study a couple of monozygotic twins discordant for the chronic fatigue syndrome: a focus on potential salivary biomarkers. J Transl Med 2013; 11: 243.
46. CIREGIA F, GIACOMELLI C, GIUSTI L, LUCACCHINI A, BAZZICHI L: Diagnosis of fibromialgia syndrome: potential biomarkers and proteomic approach. In: New Insights into Fibromyalgia .WILKE WS (Eds), Intech, 2011: 149-166.
47. BUSKILA D, ABU-SHAKRA M, NEUMANN L et al.: Balneotherapy for fibromyalgia at the Dead Sea. Rheumatol Int 2001; 20: 105-8.
48. NEUMANN L, SUKENIK S, BOLOTIN A et al.: The effect of balneotherapy at the Dead Sea on the quality of life of patients with fibromyalgia syndrome. Clin Rheumatol 2001; 20: 15-19.
49. EVCIK D, KIZILAY B, GoäKçEN E: The effects of balneotherapy on fibromyalgia patients. Rheumatol Int 2002; 22: 56-9.
50. FIORAVANTI A, PERPIGNANO G, TIRRI G et al.: Effects of mud-bath treatment on fibromyalgia patients: a randomized clinical trial. Rheumatol Int 2007; 27: 1157-61.
51. SUKENIK S, FLUSSER D, ABU-SHAKRA M: The role of spa therapy in various rheumatic diseases. Rheum Dis Clin North Am 1999; 25: 883-97.
52. ÖZKURT S, DöNMEZ A, ZEKI KARAGÜLLE M, UZUNOGLU E, TURAN M, ERDOGAN N: Balneotherapy in fibromyalgia: a single blind randomized controlled clinical study. Rheumatol Int 2012; 32: 1949-54.
53. ANDERBERG UM, UVNäS-MOBERG K: Plasma oxytocin levels in female fibromyalgia syndrome patients. Z Rheumatol 2000; 59: 373-9.
54. FIORAVANTI A, CANTARINI L, GUIDELLI GM, GALEAZZI M: Mechanisms of action of spa therapies in rheumatic diseases: what scientific evidence is there? Rheumatol Int 2011; 31: 1-8.
55. COZZI F, LAZZARIN P, TODESCO S, CIMA L: Hypothalamic-pituitary-adrenal axis dysregulation in healthy subjects undergoing mudbath applications. Arthritis Rheum 1995; 38: 724-6.
56. PIZZOFERRATO A, GARZIA I, CENNI E, PRATELLI L, TARABUSI C: Beta-endorphin and stress hormones in patients affected by osteoarthritis undergoing thermal mud therapy. Minerva Med 2000; 91: 239-45.
57. TODA M, MORIMOTO K, NAGASAWA S, KITAMURA K: Change in salivary physiological stress markers by spa bathing. Biomed Res 2006; 27: 11-4.
58. NUGRAHA B, KARST M, ENGELI S, GUTENBRUNNER C: Brain-derived neurotrophic factor and exercise in fibromyalgia syndrome patients: a mini review. Rheumatol Int 2012; 32: 2593-9.
59. NUGRAHA B, KORALLUS C, GUTENBRUNNER C: Serum level of brain-derived neurotrophic factor in fibromyalgia syndrome correlates with depression but not anxiety. Neurochem Int 2013; 62: 281-6.
60. LASKE C, STRANSKY E, ESCHWEILER GW et al.: Increased BDNF serum concentration in fibromyalgia with or without depression or antidepressants. J Psychiatr Res 2007; 41: 600-5.
61. HAAS L, PORTELA LVC, BöHMER AE, OSES JP, LARA DR: Increased plasma levels of brain derived neurotrophic factor (BDNF) in patients with fibromyalgia. Neurochem Res 2010; 35: 830-4.
62. NEECK G: Pathogenic mechanisms of fibromyalgia. Ageing Res Rev 2002; 1: 243-55.
63. LEGANGNEUX E, MORA JJ, SPREUX-VAROQUAUX O et al.: Cerebrospinal fluid biogenic amine metabolites, plasma-rich platelet serotonin and [3H]imipramine reuptake in the primary fibromyalgia syndrome. Rheumatology (Oxford) 2001; 40: 290-6.
64. BAZZICHI L, GIANNACCINI G, BETTI L et al.: Alteration of serotonin transporter density and activity in fibromyalgia. Arthritis Res Ther 2006; 8: R99.
65. ECKARDT K, SCHOBER A, PLATZBECKER B et al.: The adipokine zinc-a2-glycoprotein activates AMP kinase in human primary skeletal muscle cells. Arch Physiol Biochem 2011; 117: 88-93.